Callos Andrew 4

What Happened

• Andrew Callos, EVP and Chief Commercial Officer of CYTOKINETICS (CYTK), sold 1,709 shares on 2026-03-16 at $61.03 per share, generating proceeds of approximately $104,300. This transaction is a sale (disposition), which is often routine insider selling rather than a direct bullish signal.

Key Details

• Transaction date and price: 2026-03-16 — 1,709 shares at $61.03 each.
• Total value: ≈ $104,300.
• Transaction type: Sale (listed as "open market or private sale" in the filing).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Reported on 2026-03-16 (same day as the period of report); no late filing flag noted.
• Footnotes/controls: No 10b5-1 plan, tax-withholding, or other special footnotes were indicated in the provided details.

Context

• Sales by officers can be for many routine reasons (diversification, liquidity, tax planning) and do not by themselves prove a change in the insider’s view of the company. Purchases are typically more informative about insider confidence. This filing reports a straightforward disposition by an executive and should be considered alongside other insider transactions and company news.